Additional file 1 of Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA+ individuals without a systemic autoimmune rheumatic disease diagnosis
Creators: name: Kim, Sonya T.
name: Muñoz-Grajales, Carolina
name: Dunn, Shannon E.
name: Schneider, Raphael
name: Johnson, Sindhu R.
name: Touma, Zahi
name: Ahmad, Zareen
name: Bonilla, Dennisse
name: Atenafu, Eshetu G.
name: Hiraki, Linda T.
name: Bookman, Arthur
name: Wither, Joan
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Physiology
subject: Immunology
subject: FOS: Clinical medicine
subject: 19999 Mathematical Sciences not elsewhere classified
subject: FOS: Mathematics
subject: Cancer
subject: 110309 Infectious Diseases
subject: FOS: Health sciences
subject: Plant Biology
subject: 60506 Virology

description: Additional file 1: Supplementary Table 1. Clinical Characteristics of Progressors. Supplementary Table 2. Comparison of Baseline Clinical Characteristics in UCTD progressors and non-progressors. Supplementary Table 3. The IFN5 score as a predictor of clinical progression in ANA+ subjects lacking a SARD diagnosis, alone or in combination with other cytokines. Supplementary Figure 1. Cytokine levels in the ANA+ participant subsets stratified by sex. Scatterplots showing the results for the IFN5 score and the cytokines, IFN-α measured by high sensitivity ELISA, IFN-α measured by Simoa, CXCL-10, Galectin-9, and IFN-γ (all shown using logarithmic scales). From left to right, are shown results for healthy controls (ANA-HC), asymptomatic ANA+ individuals (ANA+NS), undifferentiated connective tissue disease (UCTD) patients, and systemic autoimmune rheumatic disease (SARD) patients (F, female; M, male). Each circle represents a single subject, with the bars indicating the median for the subjects and error bars denoting the interquartile range. Significant differences between males and females are indicated with asterisks, * p &lt; 0.05, ** p &lt; 0.01, and *** p &lt; 0.001. Supplementary Figure 2. Cytokine levels in the ANA+ participant subsets stratified by ethnicity. Scatterplots showing the results for the IFN5 score and the cytokines, IFN-α measured by high sensitivity ELISA, IFN-α measured by Simoa, CXCL-10, Galectin-9, and IFN-γ (all shown using logarithmic scales). From left to right, are shown results for healthy controls (ANA-HC), asymptomatic ANA+ individuals (ANA+NS), undifferentiated connective tissue disease (UCTD) patients, and systemic autoimmune rheumatic disease (SARD) patients (C, Caucasian; NC, non-Caucasian). Each circle represents a single subject, with the bars indicating the median for the subjects and error bars denoting the interquartile range. Significant differences between Caucasians and non-Caucasians are indicated with asterisks, * p &lt; 0.05, ** p &lt; 0.01, and **** p &lt; 0.0001. Supplementary Figure 3. Receiver operating characteristic curves for prediction of clinical progression in subjects followed for ≥ 2 years using the various cytokine measures. The clinical and serologic characteristics of the clinical progressor (n=13) and non-progressor (n=42) subjects are shown in Table 1. Results are shown for the IFN5 score and the cytokines, IFN-α measured by high sensitivity ELISA, IFN-α measured by Simoa, CXCL-10, Galectin-9, and IFN-γ. Numbers in brackets following the cytokine labels and the black dot on the curve indicate the calculated value of Youden’s Index, comparing progressors and non-progressors. The area under the curve (AUC) is shown in the bottom right corner.